Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$231.12
al cierre: Oct 21 EDT
$232.15
1.030.45%
Pre-comercialización: 6:26 AM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Equifax Inc ha un obiettivo di prezzo di consenso pari a $277, stabilito in base alle ultime valutazioni degli analisti di 29. Le ultime 3 valutazioni degli analisti sono state rilasciate da Wells Fargo, Oppenheimer y Needham il octubre 15, 2025, octubre 13, 2025 y octubre 8, 2025. Con un obiettivo di prezzo medio di $283.67 tra le Wells Fargo, Oppenheimer y Needham, c'è un implicito 22.19% upside per Equifax Inc da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
Wells Fargo
Oppenheimer
Needham
B of A Securities
UBS
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Equifax
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/15/2025 | 22.77% | Wells Fargo | $300 → $285 | Maintains | Overweight | |||
10/13/2025 | 16.73% | Oppenheimer | $279 → $271 | Assumes | → Outperform | |||
10/08/2025 | 27.07% | Needham | $295 → $295 | Reiterates | Buy → Buy | |||
10/03/2025 | 7.69% | B of A Securities | $285 → $250 | Maintains | Neutral | |||
10/01/2025 | — | Seaport Global | — | Initiates | → Neutral | |||
09/15/2025 | 27.93% | UBS | $287 → $297 | Maintains | Buy | |||
07/23/2025 | 24.92% | Citigroup | $294 → $290 | Maintains | Buy | |||
07/23/2025 | 19.75% | UBS | $315 → $278 | Maintains | Buy | |||
07/23/2025 | 20.18% | Oppenheimer | $296 → $279 | Maintains | Outperform | |||
07/23/2025 | 12% | BMO Capital | $280 → $260 | Maintains | Market Perform | |||
07/23/2025 | 17.17% | JP Morgan | $277 → $272 | Maintains | Overweight | |||
07/23/2025 | 29.23% | Wells Fargo | $310 → $300 | Maintains | Overweight | |||
07/23/2025 | 24.49% | Baird | $310 → $289 | Maintains | Outperform | |||
07/23/2025 | 3.38% | Barclays | $260 → $240 | Maintains | Equal-Weight | |||
07/10/2025 | 20.61% | BMO Capital | → $280 | Initiates | → Market Perform | |||
07/07/2025 | 33.53% | Wells Fargo | $306 → $310 | Maintains | Overweight | |||
06/23/2025 | 22.77% | B of A Securities | $300 → $285 | Downgrade | Buy → Neutral | |||
06/20/2025 | 27.07% | Needham | $295 → $295 | Reiterates | Buy → Buy | |||
06/18/2025 | 27.07% | Stifel | $277 → $295 | Maintains | Buy | |||
06/18/2025 | 29.23% | RBC Capital | $300 → $300 | Reiterates | Outperform → Outperform | |||
06/10/2025 | 31.38% | Morgan Stanley | $295 → $305 | Maintains | Overweight | |||
05/22/2025 | 27.5% | Oppenheimer | $277 → $296 | Maintains | Outperform | |||
05/21/2025 | 31.81% | Wells Fargo | $288 → $306 | Maintains | Overweight | |||
04/23/2025 | 24.06% | Wells Fargo | $284 → $288 | Maintains | Overweight | |||
04/23/2025 | 19.32% | Oppenheimer | $250 → $277 | Maintains | Outperform | |||
04/23/2025 | 29.23% | RBC Capital | $300 → $300 | Reiterates | Outperform → Outperform | |||
04/23/2025 | 27.07% | Needham | $295 → $295 | Reiterates | Buy → Buy | |||
04/14/2025 | 22.33% | Wells Fargo | $313 → $284 | Maintains | Overweight | |||
04/04/2025 | 12% | Barclays | $325 → $260 | Downgrade | Overweight → Equal-Weight | |||
03/22/2025 | 19.32% | Stifel | $281 → $277 | Maintains | Buy | |||
02/07/2025 | 27.07% | Morgan Stanley | $316 → $295 | Maintains | Overweight | |||
02/07/2025 | 40% | Barclays | $335 → $325 | Maintains | Overweight | |||
02/07/2025 | 20.18% | Oppenheimer | $286 → $279 | Maintains | Outperform | |||
02/07/2025 | 33.53% | UBS | $335 → $310 | Maintains | Buy | |||
02/07/2025 | 21.04% | Stifel | $284 → $281 | Maintains | Buy | |||
02/07/2025 | 29.23% | Needham | $325 → $300 | Maintains | Buy | |||
02/03/2025 | 34.83% | Wells Fargo | $321 → $313 | Maintains | Overweight | |||
01/28/2025 | 36.12% | Morgan Stanley | $320 → $316 | Maintains | Overweight | |||
01/15/2025 | 29.23% | Jefferies | $340 → $300 | Maintains | Buy | |||
01/10/2025 | 38.27% | Wells Fargo | $325 → $321 | Maintains | Overweight | |||
12/16/2024 | 31.38% | Exane BNP Paribas | → $305 | Upgrade | Neutral → Outperform | |||
12/12/2024 | 37.84% | Morgan Stanley | $275 → $320 | Upgrade | Equal-Weight → Overweight | |||
12/12/2024 | — | Wolfe Research | — | Downgrade | Outperform → Peer Perform | |||
11/20/2024 | 22.33% | Stifel | $305 → $284 | Maintains | Buy | |||
11/19/2024 | 21.9% | JP Morgan | $304 → $283 | Maintains | Overweight | |||
11/19/2024 | 23.2% | Oppenheimer | $315 → $286 | Maintains | Outperform | |||
10/28/2024 | 50.76% | Needham | $350 → $350 | Reiterates | Buy → Buy | |||
10/18/2024 | 43.44% | Baird | $290 → $333 | Maintains | Outperform | |||
10/18/2024 | 30.95% | JP Morgan | $300 → $304 | Maintains | Overweight | |||
10/18/2024 | 50.76% | Wells Fargo | $375 → $350 | Maintains | Overweight | |||
10/18/2024 | 50.76% | Needham | $350 → $350 | Reiterates | Buy → Buy | |||
10/08/2024 | 35.69% | Oppenheimer | $300 → $315 | Maintains | Outperform | |||
10/02/2024 | 61.53% | Wells Fargo | $340 → $375 | Maintains | Overweight | |||
10/01/2024 | 55.07% | UBS | → $360 | Initiates | → Buy | |||
09/13/2024 | 63.69% | Barclays | $300 → $380 | Maintains | Overweight | |||
09/12/2024 | 16.73% | Morgan Stanley | $250 → $271 | Maintains | Equal-Weight | |||
08/20/2024 | 32.24% | Goldman Sachs | $277 → $307 | Maintains | Neutral | |||
08/12/2024 | 46.46% | Wells Fargo | → $340 | Initiates | → Overweight | |||
07/24/2024 | 30.95% | Citigroup | $263 → $304 | Maintains | Buy | |||
07/19/2024 | 29.23% | JP Morgan | $273 → $300 | Maintains | Overweight | |||
07/19/2024 | 31.38% | Stifel | $265 → $305 | Maintains | Buy | |||
07/19/2024 | 29.23% | Oppenheimer | $272 → $300 | Maintains | Outperform | |||
07/19/2024 | 19.32% | Goldman Sachs | $246 → $277 | Maintains | Neutral | |||
07/19/2024 | 24.92% | Baird | $260 → $290 | Maintains | Outperform | |||
07/19/2024 | 37.84% | Needham | $305 → $320 | Maintains | Buy | |||
07/18/2024 | 23.2% | B of A Securities | $255 → $286 | Maintains | Buy | |||
07/09/2024 | 18.46% | Wolfe Research | → $275 | Initiates | → Outperform | |||
04/19/2024 | 9.84% | B of A Securities | $300 → $255 | Maintains | Buy | |||
04/19/2024 | 17.17% | Oppenheimer | $291 → $272 | Maintains | Outperform | |||
04/19/2024 | 3.81% | Goldman Sachs | $276 → $241 | Maintains | Neutral | |||
04/19/2024 | 17.6% | JP Morgan | $290 → $273 | Maintains | Overweight | |||
04/19/2024 | 12% | Baird | $275 → $260 | Maintains | Outperform | |||
04/18/2024 | 31.38% | Needham | $305 → $305 | Reiterates | Buy → Buy | |||
04/09/2024 | 25.35% | Oppenheimer | $273 → $291 | Maintains | Outperform | |||
02/13/2024 | 33.53% | Evercore ISI Group | $210 → $310 | Upgrade | In-Line → Outperform | |||
02/09/2024 | 31.38% | Needham | $305 → $305 | Reiterates | Buy → Buy | |||
02/09/2024 | 22.77% | Truist Securities | $270 → $285 | Maintains | Buy | |||
01/11/2024 | 17.17% | Redburn Atlantic | → $272 | Downgrade | Buy → Neutral | |||
01/09/2024 | 24.49% | Stifel | $208 → $289 | Maintains | Buy | |||
01/08/2024 | 29.23% | B of A Securities | $164 → $300 | Upgrade | Underperform → Buy | |||
01/04/2024 | 31.38% | Needham | $230 → $305 | Maintains | Buy | |||
12/29/2023 | -4.37% | Goldman Sachs | $195 → $222 | Maintains | Neutral | |||
12/19/2023 | 17.6% | Oppenheimer | → $273 | Initiates | → Outperform | |||
12/18/2023 | 35.69% | Jefferies | $200 → $315 | Upgrade | Hold → Buy | |||
12/15/2023 | 24.92% | Wells Fargo | $200 → $290 | Upgrade | Equal-Weight → Overweight | |||
12/08/2023 | 15.01% | Deutsche Bank | $218 → $267 | Upgrade | Hold → Buy | |||
12/04/2023 | -16% | Goldman Sachs | $173 → $195 | Maintains | Neutral | |||
12/01/2023 | -16% | Goldman Sachs | $173 → $195 | Maintains | Neutral | |||
11/20/2023 | 4.67% | Citigroup | → $243 | Initiates | → Buy | |||
10/20/2023 | -9.54% | Truist Securities | $250 → $210 | Maintains | Buy | |||
10/20/2023 | -13.85% | Wells Fargo | $215 → $200 | Maintains | Equal-Weight | |||
10/20/2023 | -15.57% | Morgan Stanley | $204 → $196 | Maintains | Equal-Weight | |||
10/19/2023 | -0.93% | Needham | $250 → $230 | Maintains | Buy | |||
10/02/2023 | -10.4% | Goldman Sachs | $232 → $208 | Maintains | Neutral | |||
07/24/2023 | -16% | B of A Securities | → $195 | Downgrade | Neutral → Underperform | |||
07/21/2023 | 12% | JP Morgan | $238 → $260 | Maintains | Overweight | |||
07/21/2023 | -12.13% | Morgan Stanley | $190 → $204 | Maintains | Equal-Weight | |||
07/21/2023 | 2.95% | Baird | $260 → $239 | Maintains | Outperform | |||
07/21/2023 | 7.69% | Credit Suisse | $235 → $250 | Maintains | Outperform | |||
04/25/2023 | 7.69% | Needham | → $250 | Reiterates | → Buy |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Equifax (EFX)?
El último precio objetivo de Equifax (NYSE:EFX) fue comunicado por Wells Fargo el octubre 15, 2025. La firma de analistas fijó un precio objetivo para $285.00 que espera EFX a rise dentro de 12 meses (un posible 22.77% upside). 47 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Equifax (EFX)?
La última calificación de analistas para Equifax (NYSE:EFX) fue proporcionada por Wells Fargo, y Equifax mantuvo su overweight calificación.
¿Cuándo se produjo la última revisión al alza de Equifax (EFX)?
La última revisión al alza de Equifax Inc se produjo en diciembre 16, 2024, cuando Exane BNP Paribas elevó su precio objetivo a $305. Exane BNP Paribas anteriormente tenía a neutral para Equifax Inc.
¿Cuándo fue la última revisión a la baja de Equifax (EFX)?
La última revisión a la baja de Equifax Inc se produjo en junio 23, 2025, cuando B of A Securities cambió su precio objetivo de $300 a $285 para Equifax Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Equifax (EFX)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Equifax, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Equifax se registró el octubre 15, 2025, por lo que la próxima calificación estará disponible en torno al octubre 15, 2026.
¿Es correcta la calificación de los analistas sobre Equifax (EFX)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Equifax (EFX) fue un mantuvo con un precio objetivo de $300.00 a $285.00. El precio actual al que cotiza Equifax (EFX) es de $232.15, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.